tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLLS Stock Latest News

Cellectis price target raised to $4 from $3 at Wells Fargo
The FlyCellectis price target raised to $4 from $3 at Wells Fargo
7h ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
PremiumCompany Announcements
Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
3d ago
6K
CLLS
Cellectis price target raised to $8 from $4 at Barclays
PremiumThe Fly
Cellectis price target raised to $8 from $4 at Barclays
3d ago
CLLS
Cellectis Showcases Pipeline Progress at R&D Day
PremiumCompany Announcements
Cellectis Showcases Pipeline Progress at R&D Day
4d ago
6K
CLLS
Cellectis Unveils Promising Gene Therapy Advances at ESGCT Congress
PremiumCompany Announcements
Cellectis Unveils Promising Gene Therapy Advances at ESGCT Congress
13d ago
6K
CLLS
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
PremiumRatingsCellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
2M ago
CLLS
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
Premium
Company Announcements
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
2M ago
CLLS
Cellectis Reports Q2 2025 Financial Results and Updates
Premium
Company Announcements
Cellectis Reports Q2 2025 Financial Results and Updates
3M ago
CLLS
Cellectis S.A. Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Cellectis S.A. Earnings Call: Progress Amid Challenges
3M ago
CLLS
Cellectis S.A. Reports Interim Financial Results for First Half of 2025
PremiumCompany Announcements
Cellectis S.A. Reports Interim Financial Results for First Half of 2025
3M ago
6K
CLLS
Cellectis Reports Q2 2025 Financials and Key Clinical Milestones
PremiumCompany Announcements
Cellectis Reports Q2 2025 Financials and Key Clinical Milestones
3M ago
6K
CLLS
CLLS Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CLLS Upcoming Earnings Report: What to Expect?
3M ago
CLLS
Cellectis to Announce Q2 2025 Financial Results on August 4
PremiumCompany AnnouncementsCellectis to Announce Q2 2025 Financial Results on August 4
3M ago
6K
CLLS
Cellectis files $200M mixed securities shelf
Premium
The Fly
Cellectis files $200M mixed securities shelf
4M ago
CLLS
Cellectis S.A. Announces Board Changes and Strategic Appointments
Premium
Company Announcements
Cellectis S.A. Announces Board Changes and Strategic Appointments
4M ago
6K
CLLS
Cellectis Announces Board Changes Following Shareholders’ Meeting
PremiumCompany Announcements
Cellectis Announces Board Changes Following Shareholders’ Meeting
4M ago
6K
CLLS
Cellectis Announces Board Change and Key Shareholder Meeting Agenda
PremiumCompany Announcements
Cellectis Announces Board Change and Key Shareholder Meeting Agenda
5M ago
6K
CLLS
Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
PremiumRatings
Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments
5M ago
CLLS
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
PremiumRatings
Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties
5M ago
CLLS
Cellectis price target lowered to $4 from $5 at Barclays
PremiumThe FlyCellectis price target lowered to $4 from $5 at Barclays
5M ago
CLLS
Cellectis Reports Q1 2025 Financial Results and Strategic Progress
Premium
Company Announcements
Cellectis Reports Q1 2025 Financial Results and Strategic Progress
5M ago
CLLS
Cellectis Reports Q1 2025 Financial Results and Strategic Developments
Premium
Company Announcements
Cellectis Reports Q1 2025 Financial Results and Strategic Developments
5M ago
6K
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >